NCT02859415 2022-04-05Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated3 enrolled 10 charts